Featured Research

from universities, journals, and other organizations

Preventing Tumor Cells From Refueling: A New Anti-cancer Approach?

Date:
November 24, 2008
Source:
Journal of Clinical Investigation
Summary:
Not all cells in a tumor are equal. New data, generated in mice, now suggests that targeting one set of tumor cells (specifically those in regions of the tumor rich in oxygen) can limit the growth of other tumor cells (specifically those in regions of the tumor deprived of oxygen). This approach decreased tumor growth in two models of cancer and rendered the remaining cells sensitive to irradiation.

New data, generated in mice, by Pierre Sonveaux and colleagues, at Universitι catholique de Louvain, Belgium, have identified a potential new target for anticancer therapeutics.

Not all cells in a tumor are equal, for example, some are in regions rich in oxygen, whereas others are in regions deprived of oxygen (hypoxic regions). It had been thought that the tumor cells in these two regions used the same type of fuel to generate energy, specifically glucose.

However, Sonveaux and colleagues have now shown that although hypoxic tumor cells use glucose to generate energy, well-oxygenated tumor cells use a different fuel, lactate. Further, the lactate used by the well-oxygenated tumor cells as a fuel was released from the hypoxic tumor cells as a waste product of the chemical reactions that burned glucose to generate energy, leading the authors to suggest that the different tumor cells exist in symbiosis.

More detailed analysis revealed that well-oxygenated cells took up lactate via the protein MCT1 and that inhibiting MCT1 made the well-oxygenated cells switch to using glucose as a fuel to generate energy. This disrupted the symbiotic relationship between the hypoxic and well-oxygenated tumor cells and in two mouse models of cancer led to decreased tumor growth, as the hypoxic tumor cells became deprived of glucose, and rendered the remaining cells sensitive to irradiation.

As MCT1 expression was detected exclusively in nonhypoxic regions of human cancer biopsy samples, the authors suggest that MCT1 is a potential new target for anticancer therapeutics.

In an accompanying commentary, Greg Semenza, at Johns Hopkins University School of Medicine, Baltimore, discusses this concept further as well as other therapeutic implications.


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal References:

  1. Sonveaux et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. Journal of Clinical Investigation, 2008; DOI: 10.1172/JCI36843
  2. Semenza. Tumor metabolism: cancer cells give and take lactate. Journal of Clinical Investigation, 2008; DOI: 10.1172/JCI37373

Cite This Page:

Journal of Clinical Investigation. "Preventing Tumor Cells From Refueling: A New Anti-cancer Approach?." ScienceDaily. ScienceDaily, 24 November 2008. <www.sciencedaily.com/releases/2008/11/081120171319.htm>.
Journal of Clinical Investigation. (2008, November 24). Preventing Tumor Cells From Refueling: A New Anti-cancer Approach?. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2008/11/081120171319.htm
Journal of Clinical Investigation. "Preventing Tumor Cells From Refueling: A New Anti-cancer Approach?." ScienceDaily. www.sciencedaily.com/releases/2008/11/081120171319.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins